Metamizole Sodium Bausch Health (Metamizole Sodium)

The compound blocks cyclooxygenase enzymes, lowering prostaglandin production that mediates pain and fever. In addition, it influences endogenous opioid pathways, enhancing analgesic effects without directly activating opioid receptors, resulting in combined pain‑relieving and temperature‑reducing actions.

Dosing is individualized by the prescribing clinician based on the patient’s condition, weight, and response. The medication is supplied for intramuscular or intravenous injection, and the prescriber determines the exact amount, frequency, and duration of therapy.

Safety data for Metamizole Sodium in pregnancy and lactation are limited, and the pregnancy category is unknown. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and only under professional guidance.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and necessary import documentation.

Compared with traditional NSAIDs, Metamizole Sodium offers strong analgesia and antipyresis with a lower risk of gastrointestinal irritation but carries a unique risk of blood dyscrasias such as agranulocytosis. Unlike opioids, it does not cause respiratory depression, making it a useful alternative for certain acute pain scenarios.

The injectable product should be stored at ambient temperature, below 25 °C, in its original container. Protect it from moisture, direct sunlight, and extreme temperature fluctuations. Do not freeze; inspect the solution for particulate matter before administration.

Metamizole Sodium is given by a healthcare professional via intramuscular or intravenous injection. The route, injection site, and rate of infusion are selected according to the clinical situation and the prescriber’s instructions.

The most critical adverse events include agranulocytosis, which can lead to severe infection, and life‑threatening allergic reactions such as anaphylaxis. Monitoring blood counts and observing for signs of infection or hypersensitivity are essential during therapy.

Patients with known hypersensitivity to Metamizole Sodium or other pyrazolones, those with existing blood dyscrasias, severe hepatic or renal impairment, and individuals with uncontrolled hypertension should avoid this medication. A thorough medical assessment is required before initiation.